(NASDAQ: LFCR) Lifecore Biomedical's forecast annual revenue growth rate of 9.45% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Lifecore Biomedical's revenue in 2025 is $130,309,000.On average, 3 Wall Street analysts forecast LFCR's revenue for 2026 to be $4,917,445,286, with the lowest LFCR revenue forecast at $4,783,672,765, and the highest LFCR revenue forecast at $5,081,356,426. On average, 3 Wall Street analysts forecast LFCR's revenue for 2027 to be $5,392,369,207, with the lowest LFCR revenue forecast at $5,272,407,134, and the highest LFCR revenue forecast at $5,487,894,561.
In 2028, LFCR is forecast to generate $6,601,616,517 in revenue, with the lowest revenue forecast at $6,601,616,517 and the highest revenue forecast at $6,601,616,517.